



TOBY DOUGLAS
DIRECTOR

State of California—Health and Human Services Agency
Department of Health Care Services



EDMUND G. BROWN JR.
GOVERNOR

June 26, 2012

CHDP Provider Information Notice No.: 12-04

TO: ALL CHILD HEALTH AND DISABILITY PREVENTION (CHDP)
PROGRAM PROVIDERS AND MEDI-CAL MANAGED CARE
PLANS

SUBJECT: ADMINISTRATION OF A SINGLE SUPPLEMENTAL DOSE OF
PNEUMOCOCCAL CONJUGATE VACCINE 13 VALENT (PCV13)
FOR CHILDREN WHO HAVE RECEIVED A FULL SERIES OF
PNEUMOCOCCAL CONJUGATE VACCINE 7 VALENT (PCV7)

The purpose of this CHDP Provider Information Notice is to inform you of the recommendation to administer a single supplemental dose of PCV13 (CHDP service code 88) to children who have received a full series of PCV7 (CHDP service code 67).

Pneumococcus pneumonia remains a leading cause of serious bacterial illness in children and adults. After the introduction of PCV7 in 2000, a sharp decrease in invasive pneumococcal disease occurred in disease caused by the 7 serotypes covered by the vaccine. In more recent years, however, an increase was seen in disease caused by serotypes not covered by PCV7. Because of this emergence, PCV13, which includes six additional serotypes not included in PCV7, was introduced.

According to data from an ongoing evaluation of PCV 13 by the Advisory Committee on Immunization Practices (ACIP) , 78% (86 out of 110) vaccine-eligible children diagnosed with invasive pneumococcal disease secondary to serotypes unique to PCV13 in the year after the vaccine was introduced had not received the recommended dosage.

The ACIP Recommends:

- A supplemental dose of PCV13 for all children through the age of 59 months who have completed a PCV7 series.



TOBY DOUGLAS
DIRECTOR

State of California—Health and Human Services Agency
Department of Health Care Services



EDMUND G. BROWN JR.
GOVERNOR

- A supplemental dose of PCV13 for high risk children through the age of 71 months who have completed the PCV7 series. The additional dose may be given through the age of 18.

For more information, see the October 2011 VFC letter on this subject at <http://eziz.org/>

Your continuing participation in the CHDP Program is greatly appreciated. If you have any questions about CHDP vaccine benefits or other CHDP issues, please contact your local CHDP program office.

Sincerely,

Robert Dimand, MD
Chief Medical Officer
Children's Medical Services